I also thought today's PPS action was quite weak considering the overall market. The only caveat I guess is that volume was light across the entire biotech sector, especially the small caps.
It's interesting that in a year where Big Pharma is flush with cash and chomping at the bit for M&A, that many small and mid cap Bios are still being shorted and suppressed and closer to yearly lows than yearly highs.
In reality, is EU submission the key turning point that will turn this comp around? So they submit and its confirmed they submitted...now what? We wait. We wait with confidence...in management or science? We dont even have a real CEO.